NasdaqCM - Nasdaq Real Time Price USD

Microbot Medical Inc. (MBOT)

Compare

1.0000

+0.0007

(+0.07%)

At close: December 13 at 4:00:02 PM EST

0.9952

-0.00

(-0.48%)

After hours: December 13 at 6:05:40 PM EST

MBOT Stock Gains Following FDA Submission of the LIBERTY System

Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.

Zacks yesterday

MBOT
+0.07%
GMED
Microbot Medical seeks FDA clearance for endovascular robotic system

Clearance from the US regulator is anticipated in the second quarter of next year.

Medical Device Network 2 days ago

MBOT
+0.07%
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access

Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical® Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:50am ET on December 10, 2024. The live interview can be viewed at: Benzinga All Access Live. Mr. Gadot will discuss Microbot Medical’s LIBERTY

GlobeNewswire 3 days ago

MBOT
+0.07%
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System

FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence Commercialization Following FDA 510(k) Clearance BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY® Endovascular Robotic System, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug

GlobeNewswire 3 days ago

MBOT
+0.07%
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial

MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.

Zacks last month

MBOT
+0.07%
DGX

ADUS
Microbot eyes FDA application for surgical robot after completing pivotal trial

The US robotics company is ramping up its go-to-market strategy ahead of potential US Food and Drug Administration (FDA) clearance in the second quarter of 2025 (Q2 2025).

Medical Device Network last month

MBOT
+0.07%
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025

U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinical trial. The Company remains on track to file its 510(k) submission wi

GlobeNewswire last month

MBOT
+0.07%
Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule

Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule

PREMIUM
MT Newswires 2 months ago

MBOT
+0.07%
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for ACCESS-PVI human clinical trial for LIBERTY®. As a result of the inc

GlobeNewswire 2 months ago

MBOT
+0.07%
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024BRAINTREE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial, enrolling and completing the follow up of 50% of the patients participating in the trial to evaluate the LIBERTY

GlobeNewswire 2 months ago

MBOT
+0.07%
Microbot Medical advances Liberty Robotic System telesurgery innovation

The system's capabilities are expected to address critical challenges in the healthcare sector.

Medical Device Network 3 months ago

MBOT
+0.07%
GLDAF
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.

Zacks 3 months ago

MBOT
+0.07%
DGX
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional procedures between two facilities within the Corewell Health system BRAINTREE, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announces that it en

GlobeNewswire 3 months ago

MBOT
+0.07%
Microbot Medical (MBOT) Gets Quality Certification for its System

Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.

Zacks 3 months ago

MBOT
+0.07%
UHS

DGX
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces it has received ISO 13485:2016 certification for its quality management system. Receiving ISO 13485 certification indicates that a company has developed and implemented robust policies and procedures for the development and manufacture o

GlobeNewswire 3 months ago

MBOT
+0.07%
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics

Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.

Zacks 4 months ago

MBOT
+0.07%
DGX

ABM
Microbot and Emory University to advance endovascular robotic system

Emory will explore the feasibility of integrating the Microbot’s Liberty surgical system with an imaging system.

Medical Device Network 4 months ago

MBOT
+0.07%
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System

The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous systemBRAINTREE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an agreement with Emory University, which will allow the parties to evaluate and explore the potential for a future collaboration in connection with autonomous robotics in endovascular procedures. Under the terms of the agreement, Emory

GlobeNewswire 4 months ago

MBOT
+0.07%
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trialBRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Cen

GlobeNewswire 4 months ago

MBOT
+0.07%
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

Zacks 5 months ago

MBOT
+0.07%
SYK

DVA

Performance Overview

Return	MBOT	S&P 500
YTD	-39.02%	+26.86%
1-Year	-16.67%	+30.31%
3-Year	-79.25%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Microbot Medical Inc. (MBOT)

MBOT Stock Gains Following FDA Submission of the LIBERTY System

Microbot Medical seeks FDA clearance for endovascular robotic system

Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access

Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System

Microbot Medical Stock Rises After Completing ACCESS-PVI Trial

Microbot eyes FDA application for surgical robot after completing pivotal trial

Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025

Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule

Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical advances Liberty Robotic System telesurgery innovation

Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

Microbot Medical (MBOT) Gets Quality Certification for its System

Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics

Microbot and Emory University to advance endovascular robotic system

Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

Performance Overview